Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects
Drug: Lysergic Acid Diethylamide
Other: LSD Placebo
Other: MDMA Placebo
Condition or Disease
|Study results:||No Results Available|
|Age:||25 Years to 65 Years (Adult, Older Adult)|
Clinical Trial Dates
|Start date:||Jan 01, 2021|
|Primary Completion:||Jun 30, 2022|
|Completion Date:||Jun 30, 2022|
|Study First Posted:||Aug 18, 2020|
|Results First Posted:||Sep 25, 2020|
|Last Updated:||Sep 08, 2021|
Sponsors / Collaborators
LSD is a so-called "classic" or serotonergic hallucinogen or psychedelic. Its psychedelic effects are mainly attributed to its potent partial serotonin (5-HT) 5-HT2A receptor agonism. The effects of LSD have been frequently investigated in the past in both healthy participants and patients. Several of these studies described robust and sustained effects of LSD in patients suffering from addiction, anxiety and depression. The acute subjective effects elicited by LSD are mostly positive in humans. However, psychedelic substances like LSD may also cause unpleasant subjective effects like negative thoughts, rumination, anxiety, panic, paranoia, loss of trust towards other people and perceived loss of control, depending on the dose of LSD used, the personality traits of the person consuming it (i.e. 'set'), the environment in which it is consumed (i.e. 'setting'), and other factors yet to be determined. Acute negative psychological effects are considered the main risk of psychedelic substance use in humans. Inducing an overall positive acute response to the psychedelic is critical because several studies showed that a more positive experience is predictive of a greater therapeutic long-term effect of the psychedelic. Therefore, there is a need for methods which are capable of reducing bad drug effects while enhancing good drug effects to optimize a psychedelic experience.
The present study uses 3,4-methylenedioxymethamphetamine (MDMA) as a pharmacological tool to optimize LSD's effects profile by inducing positive mood. MDMA is an amphetamine derivative which, unlike prototypical amphetamines, predominantly enhances serotonergic neurotransmission via release of 5-HT through the serotonin transporter (SERT). Furthermore, MDMA is known to trigger oxytocin release which may contribute to its effects to increase trust, prosociality, and enhanced empathy. The state of well-being induced by MDMA including increased activation and emotional excitation is known to be associated with a better response to psychedelics. Due to its psychological profile, MDMA could be a reliable pharmacological tool to serve as an optimizer of a psychedelic experience by inducing positive emotions.
This clinical trial is recruiting
Are you interested in participating in this trial or others? We'd love to help.
|Other IDs:||BASEC 2020-01829|